Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agenus Inc. - Common Stock (NQ:AGEN)

3.187 +0.047 (+1.50%)
Streaming Delayed Price Updated: 11:05 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 99,983
Open 3.180
Bid (Size) 3.180 (800)
Ask (Size) 3.190 (1,100)
Prev. Close 3.140
Today's Range 3.090 - 3.200
52wk Range 1.380 - 7.340
Shares Outstanding 348,875,959
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
From Agenus Inc.
Via Business Wire
News headline image
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire

Performance

YTD
N/A
N/A
1 Month
-23.6%
-23.6%
3 Month
-19.1%
-19.1%
6 Month
-47.5%
-47.5%
1 Year
+3.1%
+3.1%

More News

Read More
News headline image
Earnings Scheduled For November 10, 2025 ↗
Via Benzinga
News headline image
Examining the Future: Agenus's Earnings Outlook ↗
Via Benzinga
News headline image
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
From Agenus Inc.
Via Business Wire
News headline image
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC
From Agenus Inc.
Via Business Wire
News headline image
AGENUS INC (NASDAQ:AGEN) Reports Mixed Q3 2025 Earnings, Driven by One-Time Gain ↗
Via Chartmill
News headline image
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
From Agenus Inc.
Via Business Wire
News headline image
Insights Ahead: Agenus's Quarterly Earnings ↗
Via Benzinga
News headline image
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
Via MarketMinute
Topics Intellectual Property
News headline image
Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report
From Agenus Inc.
Via Business Wire
News headline image
Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights
From Agenus Inc.
Via Business Wire
News headline image
France Grants Reimbursed Compassionate Access (AAC) for Agenus’ BOT/BAL in Refractory MSS Metastatic Colorectal Cancer
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
From Agenus, Inc.
Via Business Wire
News headline image
Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025
From Agenus Inc.
Via Business Wire
News headline image
Monday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Agenus Posts 48% Q2 Revenue Miss ↗
Via The Motley Fool
News headline image
Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025
From Agenus Inc.
Via Business Wire
News headline image
Earnings Scheduled For August 11, 2025 ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Agenus’ BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3
From Agenus Inc.
Via Business Wire

Frequently Asked Questions

Is Agenus Inc. - Common Stock publicly traded?
Yes, Agenus Inc. - Common Stock is publicly traded.
What exchange does Agenus Inc. - Common Stock trade on?
Agenus Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Agenus Inc. - Common Stock?
The ticker symbol for Agenus Inc. - Common Stock is AGEN on the Nasdaq Stock Market
What is the current price of Agenus Inc. - Common Stock?
The current price of Agenus Inc. - Common Stock is 3.187
When was Agenus Inc. - Common Stock last traded?
The last trade of Agenus Inc. - Common Stock was at 01/02/26 11:05 AM ET
What is the market capitalization of Agenus Inc. - Common Stock?
The market capitalization of Agenus Inc. - Common Stock is 1.11B
How many shares of Agenus Inc. - Common Stock are outstanding?
Agenus Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.